SYSTEMIC SCLEROSIS (SSC)

This early-phase study tests a new treatment called BCT301 for people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard therapies. BCT301 uses immune cells made from stem cells to target and attack faulty immune cells. The main goal is …

This early-stage study tests whether a single infusion of a patient's own modified immune cells (CAR-T cells) is safe for adults with severe autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma that haven't improved with standard treatments. The main goal is to ch…

This early study tests a new treatment called HN2302 in 12 adults with lupus or scleroderma. The goal is to see if it is safe and how well it works. The treatment is a type of cell therapy that may help control the immune system.

This early study tests a new drug, cizutamig, in 10 adults with systemic sclerosis, a disease that causes skin hardening and organ problems. The main goal is to see if the drug is safe and how the body handles it. This is a very early step and does not aim to cure the disease.

This early-stage study tests a new medicine called GB261 in 10 people with systemic sclerosis, a disease that causes skin thickening and organ damage. The main goal is to check safety and how the body handles the drug. Participants must have moderate to severe skin involvement an…

This study will use a high-tech blood test (mass spectrometry) to look at different immune cells in 500 people with various autoimmune diseases and healthy volunteers. The goal is to find patterns that could help doctors screen for and diagnose these conditions earlier. No new tr…

This study will measure a blood protein called FAP, which is linked to tissue scarring and inflammation, in people with rheumatoid arthritis or systemic sclerosis and in healthy volunteers. Researchers want to see if FAP levels relate to disease activity and lung involvement. Par…